This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / UniQure Faces Class Action Lawsuit
Business class action lawsuit

UniQure Faces Class Action Lawsuit

Analysis based on 13 articles · First reported Feb 11, 2026 · Last updated Feb 23, 2026

Sentiment
-60
Attention
4
Articles
13
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the uncertainty surrounding UniQure's drug development and the potential financial implications of the class action lawsuit. UniQure's stock price experienced a significant decline, reflecting investor concern.

Biotechnology Legal Services
Event Summary

A class action lawsuit has been filed against UniQure N.V. by Berger Montague PC on behalf of investors. The lawsuit alleges that UniQure misrepresented and failed to disclose crucial information regarding its drug AMT-130 for Huntington s disease. Specifically, the complaint states that the design of UniQure's Pivotal Study was not fully approved by the United States===Food and Drug Administration, and the company downplayed potential delays in its Biologics License Application timeline. Following UniQure's disclosure on November 3, 2025, that the United States===Food and Drug Administration did not agree to use Phase I/II data as primary evidence for a BLA submission, UniQure's stock price fell by over 49%.

Key Actions
100 Berger Montague filed class action lawsuit UniQure
95 UniQure stock price fell
90 UniQure disclosed United States===Food and Drug Administration's disagreement on drug study
Entities Involved
stock
UniQure
UniQure is facing a class action lawsuit due to alleged misrepresentations regarding its drug AMT-130 and its interactions with the United States===Food and Drug Administration. This led to a significant drop in its stock price.
Importance 100 Sentiment -80
priv
Berger Montague
Berger Montague, a national plaintiffs' law firm, filed the class action lawsuit against UniQure. The firm is actively seeking lead plaintiffs for the class.
Importance 80 Sentiment 70
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration did not fully approve the design of UniQure's Pivotal Study for AMT-130 and did not agree that Phase I/II data could serve as primary evidence for a BLA submission, leading to delays.
Importance 70 Sentiment 0
exch
Nasdaq
UniQure's stock is traded on Nasdaq, and its price experienced a significant decline following the disclosure of the United States===Food and Drug Administration's stance.
Importance 10 Sentiment 0
Relationships
UniQure related ↔ Berger Montague
UniQure related ↔ United States===Food and Drug Administration
Berger Montague related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.